91337-45-0

Basic information

• Product Name: 1H-Benzimidazol-2-amine,1-butyl-(9CI)
• Synonyms: 1H-Benzimidazol-2-amine,1-butyl-(9CI);1-butyl-1H-benzimidazol-2-amine;1-butyl-1H-benzimidazol-2-amine hydrochloride;Albb-006213;1-butyl-1H-benzimidazol-2-amine(SALTDATA: FREE);(1-butylbenzimidazol-2-yl)amine hydrochloride;1-butyl-1H-benzo[d]imidazol-2-amine hydrochloride;1-butyl-2-benzimidazolamine hydrochloride
• CAS NO: 91337-45-0
• Molecular Formula: C₁₁H₁₅N₃
• Molecular Weight: 189.26
• Product Categories: BENZIMIDAZOLE
• Mol File: 91337-45-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 360.6°C at 760 mmHg
• Flash Point: 171.9°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 2.2E-05mmHg at 25°C
• Refractive Index: 1.61
• CAS DataBase Reference: 1H-Benzimidazol-2-amine,1-butyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazol-2-amine,1-butyl-(9CI)(91337-45-0)
• EPA Substance Registry System: 1H-Benzimidazol-2-amine,1-butyl-(9CI)(91337-45-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 91337-45-0(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazol-2-amine, 1-butyl-(9CI) is a chemical compound with the molecular formula C11H14N2. It is a derivative of benzimidazole, which is a bicyclic heteroaromatic organic compound. This chemical is known to have various biological activities, including antifungal and antibacterial properties. It can also act as an inhibitor of the enzyme dihydroorotate dehydrogenase, making it a potential candidate for antiviral and anticancer drugs. Additionally, 1H-Benzimidazol-2-amine, 1-butyl-(9CI) has been studied for its potential use as a corrosion inhibitor in industrial applications. Overall, this compound has diverse properties and potential applications in pharmaceuticals and industrial chemistry.

InChI:InChI=1/C11H15N3/c1-2-3-8-14-10-7-5-4-6-9(10)13-11(14)12/h4-7H,2-3,8H2,1H3,(H2,12,13)

Upstream product

• 934-32-7 1H-benzimidazol-2-amine 
• 109-65-9 1-bromo-butane 
• 95-54-5 1,2-diamino-benzene 
• 542-69-8 1-iodo-butane 

Downstream Products

• 1355394-42-1 ethyl-(9-butylimidazo[1,2-a]benzimidazolyl-2)acetate hydrochloride 
• 1355770-08-9 ethyl-(9-butylimidazo[1,2-a]benzimidazolyl-2)acetate 
• 825601-30-7 C₁₈H₂₀ClN₃ 
• 79349-49-8 9-Butyl-2-phenylimidazo<1,2-a>benzimidazole 
• 119294-93-8 2-Bromomethyl-3-methoxycarbonyl-9-butylimidazo<1,2-a>benzimidazole 
• 119294-90-5 9-Butyl-2-methyl-9H-benzo[d]imidazo[1,2-a]imidazole-3-carboxylic acid methyl ester 
• 117651-73-7 N-Adamantan-1-yl-2-(3-butyl-2-imino-2,3-dihydro-benzoimidazol-1-yl)-acetamide; hydrochloride 

Relevant articles and documents

Hit-to-lead optimization of novel benzimidazole phenylacetamides as broad spectrum trypanosomacides

Trypanosoma cruzi and Trypanosoma brucei are the parasitic causative agents of Chagas disease and human African trypanosomiasis (HAT), respectively. The drugs currently used to treat these diseases are not efficacious against all stages and/or parasite sub-species, often displaying side effects. Herein, we report the SAR exploration of a novel hit, 2-(4-chlorophenyl)-N-(1-propyl-1H-benzimidazol-2-yl)acetamide previously identified from high throughput screens against T. cruzi, Trypanosoma brucei brucei and Leishmania donovani. An informative set of analogues was synthesized incorporating key modifications of the scaffold resulting in improved potency whilst the majority of compounds retained low cytotoxicity against H9c2 and HEK293 cell lines. The SAR observed against T. cruzi broadly matches that observed against T.b. brucei, suggesting the possibility for a broad-spectrum candidate. This class of compounds therefore warrants further investigation towards development as a treatment for Chagas disease and HAT. This journal is

TOLL-LIKE RECEPTOR AGONISTS

Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivatives thereof, prodrugs thereof, salts thereof, or stereoisomers thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines, as well as for other therapeutic purposes described herein.

Synthesis and?QSAR studies of?novel 1-substituted-2-aminobenzimidazoles derivatives

A series of novel 1-substituted-2-aminobenzimidazole derivatives were synthesized. The structures of the synthesized compounds were confirmed by 1H-NMR spectra and by elemental analysis. Acute toxicities of these compounds were detected on mice via toxicity (logLD50). QSAR analysis of these chemicals was studied on the relationship between acute toxicity and the octanol/water partition coefficient (LogP). The products were identified by the results of elemental analysis and 1H-NMR spectra. The toxicity (logLD50) of 2-aminobenzimidazole 1-substituents were correlated well with the partition coefficient LogP, r = 0.9243. The bioactivity (toxicity) of 2-aminobenzimidazoles can be predicted by the molecular structural parameter such as LogP.